PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis

Ze-Jun Zhou; Ping Zhan; Yong Song

doi:10.3978/j.issn.2218-6751.2015.03.02

PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis

Transl Lung Cancer Res. 2015 Apr;4(2):203-8. doi: 10.3978/j.issn.2218-6751.2015.03.02.

Authors

Ze-Jun Zhou¹, Ping Zhan¹, Yong Song¹

Affiliation

¹ Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medical, Nanjing 210002, China.

PMID: 25870804
PMCID: PMC4384212
DOI: 10.3978/j.issn.2218-6751.2015.03.02

Abstract

Background: Observational studies on the prognostic role of programmed cell death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) are controversial.

Methods: To clarify the impact of PD-L1 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios (HR) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival.

Results: A total of five studies with 877 patients were evaluable for this meta-analysis. Our results suggested that PD-L1 overexpression had a poor impact on survival of patients with NSCLC, the HR (95% CI) was 1.43 (1.24-1.63) overall, 1.51 (1.24-1.7954) in Asian patients, 1.35 (1.08-1.63) in non-Asian patients. Moreover, there was no heterogeneity between the studies.

Conclusions: PD-L1 overexpression indicates a poor prognosis for patients with NSCLC.

Keywords: Programmed cell death-ligand 1 (PD-L1); lung cancer; meta-analysis; prognosis.